Mackenzie Financial
VTGN icon

Mackenzie Financial’s VistaGen Therapeutics VTGN Stock Holding History

Mackenzie Financial’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-458
Closed -$1.71K – 1647
2023
Q1 		$1.71K Hold
458
– – ﹤0.01% 1512
2022
Q4 		$1.42K Hold
458
– – ﹤0.01% 1423
2022
Q3 		$2K Hold
458
– – ﹤0.01% 1425
2022
Q2 		$12K Buy
458
+112
+32% +$3.96K ﹤0.01% 1452
2022
Q1 		$13K Hold
346
– – ﹤0.01% 1397
2021
Q4 		$20K Sell
346
-28
-7% -$1.82K ﹤0.01% 1415
2021
Q3 		$31K Buy
+374
New +$32.5K ﹤0.01% 1416

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mackenzie Financial's VTGN Position: Q2 2023 in Review

Mackenzie Financial sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 458 shares — an estimated $1.71K sold.

Mackenzie Financial first reported a position in VTGN in Q3 2021 and held it in 7 quarters. The position peaked at $31K in Q3 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • Mackenzie Financial reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Mackenzie Financial sold 458 VistaGen Therapeutics shares in Q2 2023, an estimated $1.71K.
  • Mackenzie Financial first reported a position in VistaGen Therapeutics in Q3 2021 and held it in 7 quarters.
  • Mackenzie Financial's VistaGen Therapeutics position peaked at $31K in Q3 2021.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Mackenzie Financial's 13F filing for Q2 2023, filed 3 Aug 2023.